axicabtagene ciloleucel
gilead sciences,daiichi sankyo
['lymsm', 'axi-cel', 'lymphoma']
congress #asco22 | describes outcomes by ethnicity of pts with #lbcl given axi-cel. n=1389. orr was 74% for white, 57% for african american, 67% for asian &amp; 73% for hispanic pts. aa race was associated with worse orr &amp; cr rate vs white #lymphoma #lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm